Insud Pharma
↗Madrid, Spain
Insud Pharma is a global pharmaceutical group founded in 1977, operating across the entire pharmacochemical value chain. The company specializes in the research, development, manufacturing, and commercialization of Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms (FDFs), and branded pharmaceutical products for human and animal health.
The group operates through several key business units, including Chemo (APIs and generics), Exeltis (branded pharmaceuticals with a focus on women's health and CNS), and maintains a significant stake in mAbxience (biotechnology and biosimilars). With a presence in over 50 countries, the company leverages a network of manufacturing plants and R&D centers to provide accessible and high-quality therapeutic solutions.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:CDMO/CMO, Generics, Biopharmaceuticals
SIZE & FINANCIALS
Employees:5001-10000
Founded:1977
Ownership:private
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Monoclonal antibodies, Biosimilars
Active Trials:27
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Chemo, Exeltis, mAbxience (40% stake)
Key Partnerships:Fresenius Kabi (acquired majority stake in mAbxience)
COMPETITION
Position:Leader
Competitors:Anthem Biosciences, Patheon, Abzena
LEADERSHIP
Key Executives:
Lucas Sigman - CEO
Scientific Founders:Silvia Gold, Hugo Sigman
LINKS
Website:insudpharma.com
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Insud Pharma and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Insud Pharma. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.